Bain said its decision to buy Mitsubishi Tanabe is due to the “strong growth potential” of Japan’s healthcare industry.

Bain Capital said the deal came about following several recent initiatives by the Japanese government and regulators to ...

U.S. private equity firm Bain Capital has bought Mitsubishi Tanabe Pharma in a deal worth 510 billion yen ($3.4 billion), ...

Bain Capital entered a deal to acquire Mitsubishi Tanabe Pharma Corporation (MTPC) from Mitsubishi Chemical Group for 510 ...

The investment firm is acquiring Mitsubishi Tanabe Pharma in a deal valued at $3.3 billion. Elsewhere, Bausch + Lomb hasn’t ...

The Mitsubishi Chemical Group is selling its centuries-old pharmaceutical business to Bain Capital in a carve-out worth about ...

Bausch + Lomb's efforts to sell have so far been unsuccessful. Meanwhile, KKR is aggressively pursuing a deal for Fuji Soft.

Following rumblings of a private equity bidding war late last year, Bain Capital has emer | Bain Capital is laying out 510 ...

Mitsubishi Corp has recorded an impairment charge of Y52.2bn ($342.4m) on its offshore wind projects in Japan.

Today, we have a look at the White House's reported plans to make major cuts across federal health agencies. Also, Eli Lilly is expanding the ...

I Mitsubishi Chemical Group Corporation (MCG) hereby announces that it has resolved, at a meeting of the Board of Directors held today, to ...

Private equity firm Bain Capital agreed to acquire Mitsubishi Chemical Group’s pharmaceutical unit, adding to a dealmaking ...